Document is current
Any future updates will be listed below
-
Authors
Vos, Stephanie J. B. https://orcid.org/0000-0002-2045-9818
Delvenne, Aurore https://orcid.org/0000-0001-8724-3010
Jack, Clifford R. Jr https://orcid.org/0000-0001-7916-622X
Thal, Dietmar R. https://orcid.org/0000-0002-1036-1075
Visser, Pieter Jelle
- License Information
-
More Information
Article History
Accepted: 4 April 2024
First Online: 9 May 2024
Competing interests
: S.J.B.V. has received funding from ZonMW (SNAP VIMP grant no. 7330505021), Stichting Adriana van Rinsum-Ponssen and the EPND project, which received funding from the European Commision, IMI 2 Joint Undertaking (JU) under grant agreement no. 101034344. The IMI JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. D.R.T. has received speakers’ honoraria from Biogen and travel reimbursement from UCB and has collaborated with Novartis Pharma AG, Probiodrug, GE-Healthcare and Janssen Pharmaceutical Companies. He receives funding from Stichting Alzheimer Onderzoek (SAO/FRA 2020/017), Fonds Wetenschappelijk Onderzoek (Vlaanderen) (G0F8516N, G065721N), Alzheimer Association (22-AAIIA-963171) and KU-Leuven Internal Funding (C14/22/132; C3/20/057). P.J.V. has received funding from the European Commission, IMI 2 JU, AMYPAD grant no. 115952; European Commission, IMI 2 JU, RADAR-AD grant no. 806999; and European Commission, IMI 2 JU, EPND grant no. 101034344. He has also received funding from Zon-MW, Redefining Alzheimer’s disease, grant no. 733050824736; and Biogen (Amyloid Biomarker Study Group). Grants were paid to the university. A.D. and C.R.J. declare no competing interests.
